openPR Logo
Press release

New Drug Combination Could Control Blood Sugar And Weight In Diabetes

New Drug Combination Could Control Blood Sugar And Weight

Scientists have shown that adding an experimental cancer drug to a widely used diabetes treatment improves blood sugar control and weight loss in mice, according to a study published on 22nd, Dec. in eLife.
The results pave the way for clinical studies of the new drug combination as a more effective long-term treatment for millions of people with diabetes and obesity.
Glucagon-like peptide 1 agonists (GLP-1 analogs) are a relatively new class of drugs that reduce blood sugar levels and lower body weight. They partially function by binding to the glucagon-like peptide 1 receptor on pancreatic beta cells, which leads the cells to produce insulin. But not all patients achieve normalisation of blood glucose control with GLP-1 drugs, and very few achieve full reversal of obesity.
"We have previously shown that prolonged association of the GLP-1 agonists with the glucagon-like peptide 1 receptor supports insulin secretion in pancreatic beta cells," explains project team leader Dr. Prasenjit Mitra of the Dr. Reddy's Institute of Life Sciences. "This led us to see whether we could enhance the effects of GLP-1 agonism on regulating glucose levels with a complementary therapy."
The team started with a library of potential drugs and tested them in pancreatic beta cells to see if they enhanced the effects of a GLP-1 drug on incretin receptor activity, by measuring a second messenger molecule called cAMP. They found four molecules that enhanced GLP-1 drug activity. The most effective one, MS-275 (also called entinostat), generated 3.5 times the cAMP levels than the GLP-1 drug alone. MS-275 is a member of a drug family called class 1 HDAC inhibitors that are being investigated as treatments for other diseases including cancer.
Given the synergistic effect of the drugs in pancreatic beta cells, the team tested whether their findings would hold true in obese mice, fed a high-fat diet. Shilpak Bele, the graduate student under Dr. Mitra's direction, and other team members found that mice treated with the combination of GLP-1 agonist and MS-275 had a much lower fasting glucose level than control mice that were sustained with repeat dosing. Where a high-fat diet increased fasting blood sugar in the untreated mice, the mice on the combination treatment remained in control.
Given these effects on blood sugar, the team explored whether the combination treatment also minimised weight gain. Mice given the combination treatment had a significant and sustained reduction in their food intake, which resulted in weight loss. When treatment was interrupted, the mice regained weight. Once the treatment was resumed, only the mice receiving the combination treatment showed significant weight loss again.
"GLP-1 drugs have emerged in the last decade as unique medicines that provide substantial improvements in glycemic control and body weight; however, they seldom achieve full metabolic recovery or help treat associated comorbidities such as body weight," Dr. Mitra explains. "Our results suggest that the class 1 HDAC inhibitor MS-275 can significantly enhance the action of GLP-1 drugs, more effectively normalising blood glucose and reducing weight gain. This lays the foundation for clinical studies of combinations of GLP-1/HDAC inhibitors for the long-term management of diabetes and obesity in humans."
Semaglutide is a medication used for the treatment of type 2 diabetes. It acts like human glucagon-like peptide-1 (GLP-1) so that it increases insulin secretion, thereby increasing sugar metabolism. Liraglutide is a GLP-1 receptor agonist used to treat diabetes mellitus type 2 and obesity. 

Hunan Huateng Pharmaceutical Co. Ltd.
Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, P.R. China
zip code: 410205
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818
Website: https://en.huatengsci.com/
Email:sales@huatengusa.com

Huateng Pharma is a leading supplier for a variety of pharmaceutical intermediates used in research and development. We can provide antidiabetic drugs intermediates such as liraglutide intermediates and semaglutide intermediates for your research. We can make scale-up production with capacities varying from gram to kilograms and multi tons.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release New Drug Combination Could Control Blood Sugar And Weight In Diabetes here

News-ID: 2217347 • Views: 498

More Releases from Hunan Huateng Pharmaceutical Co. Ltd.

Huateng Pharma Develops Systemic Antiparasitic Agent Fluralaner
Fluralaner is a systemic insecticide and acaricide that can be administered orally or topically. Bravecto is the trade name. The U.S. Food and Drug Administration (FDA) approved it for flea treatment in dogs under the trade name Bravecto in May 2014 and for topical treatment in cats in November 2019. Fluralaner is a novel isooxazoline broad-spectrum insecticide that acts on γ-aminobutyric acid (GABA) receptors and has good activity against ticks, fleas,
Huateng Pharma Develops Intermediates of Carfilzomib For Multiple Myeloma
Carfilzomib, a proteasome inhibitor, is indicated for the treatment of patients with multiple myeloma. Multiple myeloma (multiple myeloma, MM) is a malignant tumor originating from the B cell lineage, characterized by the clonal proliferation of malignant plasma cells in the bone marrow microenvironment, causing fractures and bone marrow failure, and is the second most common blood system disease in the world Tumors cannot be cured by traditional chemotherapy regimens. Bortezomib is the
Huateng Pharma Develops Intermediates of Semaglutide For TD2
According to the latest IDF Diabetes map, the global prevalence of diabetes reached 10.5% in 2021, with 537 million adults living with diabetes. China has become a disaster zone for diabetes, with the largest number of adults with diabetes in the world. In the past 10 years (2011-2021), the number of people with diabetes in China increased from 90 million to 140 million, an increase of 56%. The total number
The Future of Treatment For Type 2 Diabetes
Although the treatment of type 2 diabetes (T2DM) has made impressive progress in the past few decades, researchers are constantly searching for new treatments. How to better control blood glucose and reduce diabetes-related complications has become a hot topic in the field of T2DM research. Previously, The Lancet Diabetes Endocrinology published an in-depth review detailing novel therapeutic targets for T2DM, mechanisms of drug action, and corresponding hypoglycemic efficacy. It involves innovation

All 5 Releases


More Releases for Mitra

Intercity Electric Bus Market Precise Outlook 2021 - BYD Company Ltd., Ebusco, E …
The Global Intercity Electric Bus Market is expected to reach an approximate CAGR of 20.3% by 2026. The Market Research on the “Intercity Electric Bus Market 2021-2026”, now available with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The Intercity Electric Bus market report offers an overview of top company profiles with the business value and demand
JMA Pilani Celebrates Crystal Jubilee with Sunderkand Path by Shri Mitra Mandal …
It is indeed a matter of great pride that, Smt Jamuna Mishra Academy JMA founded in the year 2004 by a visionary NRI doctor BrijMohan Mishra at Pilani considered as Oasis in the desert state of Rajasthan completed 15 years in 2019. JMA is a Co-educational English Medium School with Experienced Teachers, Spacious Classrooms and Modern Amenities designed to impart Quality Education combined with All Round Personality Development and lay
Mitra Mandal Devi Durga Puja - Pilani Rajasthan Springs to Fun and Frolic in Fal …
Located in the heart of Shekhawati, Pilani considered the Oasis in the desert state of Rajasthan is well known in India today for various top ranking establishments which include one of the Institutions of Eminence Birla Institute of Technology and Science BITS Pilani, CSIR CEERI, L.N. Birla Naturopathy & Yoga Kendra and Birla Science Centre. Durga, in Sanskrit means "She who is incomprehensible or difficult to reach” and as the
Success in the Business World: Rajem Kumar was Given the 2012 Laghu Udyog Mitra …
Discover the accomplishments of a handful of SME specialists in India. Check out this post to know who these successful entrepreneurs are. Rajem Kumar, SME World Chief Editor, was chosen as this year’s recipient for Laghu Udyog Mitra Award for his outstanding contribution in the growth and development of the Small Medium Enterprise (SME) industry in India. Aside from Kumar, Dr. HP Kumar, Chairman and Managing Director of National Small Industries Corporation,
Dr. Amitava ‘Babi’ Mitra joins VIT University, Jaipur as its first President …
He is an alumnus of BITS Pilani and was formerly Executive Director at the Massachusetts Institute of Technology - MIT USA Dr. Amitava ‘Babi’ Mitra joined recently as the President and Vice Chancellor of the newly created VIT University, Jaipur. A proven international leader in delivering technology-enabled educational solutions in demanding environments in the US and India, Dr. Mitra has successfully led 40-600 people entrepreneurial ventures at MIT, USA, BITS, Pilani,
Pilani Rajasthan Springs to Fun and Frolic in Fall - Mitra Mandal Devi Puja
Located in the heart of Shekhawati region of Rajasthan, Pilani is well known in India today for various top ranking educational institutions, CSIR Laboratory CEERI as well as the upcoming BrahMos Missile Assembly Project Unit. Durga, in Sanskrit means "She who is incomprehensible or difficult to reach” and as the Mother of the Universe bestowed with infinite power she is the symbol of female dynamism. This year Pilani had over a